JLK (CEO Dongmin Kim), a medical artificial intelligence (AI) company, announced on the 30th that it has signed a joint research agreement with Japan's National Cerebral and Cardiovascular Center (NCVC) to evaluate the clinical performance of AI medical solutions.
NCVC, established in 1977, is Japan's leading national medical institution specializing in circulatory and cerebrovascular diseases. It is a research and treatment base hospital with high authority in the fields of stroke and cardiovascular diseases.
The joint study will primarily evaluate the clinical performance of JLK's brain CT perfusion solution (JLK-CTP) and brain MR perfusion solution (JLK-PWI) using data from Japanese patients. Through clinical data analysis, both organizations plan to objectively verify how effectively these solutions can contribute to stroke diagnosis and treatment decision-making.
JLK plans to use this research to strengthen its position in the Japanese market. Having secured seven approvals from the Pharmaceuticals and Medical Devices Agency (PMDA) to date, the company aims to leverage the results of this study to pursue additional approvals and increase product adoption among Japanese medical professionals, thereby establishing a stable sales base.
JLK CEO Kim Dong-min said, “This joint research with NCVC is an important step in verifying JLK’s technological prowess by Japan’s top-level expert institution,” and added, “Based on the research results, we plan to promote entry into Japan’s health insurance C2 new technology fee system and further strengthen trust in the Japanese market.”
- See more related articles
You must be logged in to post a comment.